Lupus & antiphospholipid syndrome
WNT16 as a promising biomarker for systemic lupus erythematosus and its role in regulating cell proliferation and apoptosis
Authors' conclusion
Serum WNT16 levels effectively differentiate SLE patients from healthy controls and individuals with other autoimmune disorders.
Study context
- Population
- Systemic lupus erythematosus (SLE) patients, healthy controls and disease controls (rheumatoid arthritis (RA) and Sjögren's syndrome)PBMC cohort: 35 SLE, 25 healthy
- Comparison
- Serum WNT16 in SLE vs healthy controls (HC), RA and Sjögren's syndrome (SS)
- SLEn = 162
- HCn = 96reference
- Outcome
- Diagnostic potential of serum WNT16 for SLE (ROC analysis)
Methodological detailscase-control, knockdown assay in Jeko-1 cells
- Case-control
- Knockdown assay in Jeko-1 cells
Performance
As reported in the abstract
Diagnostic performance of WNT16 for SLE identification
AUC
0.809
SLE vs HC
AUC
0.760
SLE vs RA
AUC
0.710
SLE vs SS
Further findings
WNT16 mRNA in peripheral blood mononuclear cells (PBMCs)
- Significantly lower in SLE than HC
Correlations of WNT16 protein in SLE
- Weak positive correlation with alkaline phosphatase and lymphocyte percentage
- Weak negative correlation with LDL, neutrophil percentage, pleurisy and disease activity
WNT16 knockdown in Jeko-1 cells
- Impairs cell proliferation and enhances apoptosis
Original publication
WNT16 as a promising biomarker for systemic lupus erythematosus and its role in regulating cell proliferation and apoptosis. Clin Exp Rheumatol. Published 18 December 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →